Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Trial Profile

An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2019

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel; Prasugrel; Ticagrelor; Vitamin K antagonists
  • Indications Thromboembolism
  • Focus Adverse reactions; Registrational
  • Acronyms PIONEER-AF-PCI
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association
    • 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology.
    • 13 Jun 2018 Results of risk-benefit profile of NOAC based antithrombotic regimens versus VKA-based triple therapy by using data from two studies (PIONEER AF-PCI and RE-DUAL PCI) published in the American Heart Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top